Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed

This article was originally published in The Pink Sheet Daily

Executive Summary

A change in projected discounts resulted from ICER’s decision to broaden its consideration of the benefit of PCSK9 treatment to span a patient’s lifetime, including outcomes in patients over 75.


Related Content

Amgen Faces New ICER Roadblock To Repatha Reimbursement
Repatha Pricing Pressure Might Actually Increase After Outcomes Trial
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts